You are here
Photos from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIAMS staff with Accelerating Medicines Partnership collaborators.
Dr. Katz and Col. Hopkins
NIAMS Director Dr. Stephen I. Katz and NASA Astronaut Col. Michael S. Hopkins.
NIAMS Director Stephen I. Katz with basketball player Isaiah Austin during a Congressional briefing on Marfan Syndrome.
NIAMS Congressional Tour Day
NIAMS staff and Congressional staffers gather for the NIAMS Congressional Tour Day.
The American Society for Bone and Mineral Research
NIAMS Director Dr. Stephen I. Katz receives award from the American Society for Bone and Mineral Research.
Outreach and Education Day
NIH Director Francis Collins, M.D., Ph.D., addressed the NIAMS Coalition on November 6, 2013, at the fourth bi-annual Outreach and Education Day event. The Coalition is a group of nearly 90 professional and voluntary organizations concerned with the programs of the NIAMS.
NIAMS’ Pediatric Translational Research Branch
Shown during HHS Secretary Kathleen Sebelius’s visit to the Children’s Inn at NIH are (from l): Inn CEO Kathy Russell, Mr. Carlos Martinez (father), Ms. Tia Ford (friend), Sec. Sebelius, Ms. Kayla Martinez (patient), Dr. Francis Collins (NIH Director), Ms. Dorelia Rivera (mother) and Dr. Raphaela Goldbach-Mansky of NIAMS’ Pediatric Translational Research Branch.
Basic, Translational, and Clinical Osteoarthritis (OA) Research
On April 30, 2013, NIH grantees, clinicians and patients met NIAMS leadership and staff to discuss how findings from basic, translational and clinical osteoarthritis (OA) research can be combined with recent advances in inflammation research to enhance understanding of the early processes involved in the initiation and onset of disease. The discussion prompted possible avenues for interventions to prevent or delay OA development. Part of the Institute’s scientific planning process, the full-day roundtable addressed topics including the impact of inflammation, the evidence for activation of inflammation in the development of OA, and the relationship of inflammation to pain and other pathogenic pathways in the disease. The group also discussed how interventions during the initial injury of a joint and the ensuing healing process might influence the later development of OA. Participants included NIAMS Deputy Director Dr. Robert Carter (front, fourth from r) and staff, including Drs. Joan McGowan (front, third from l), Bernadette Tyree (front, fourth from l) and Gayle Lester (front row, third from r).
NIAMS Scientific Director John O’Shea
In 2012, the U.S. Food and Drug Administration approved tofacitinib to treat rheumatoid arthritis. Tofacitinib targets Janus kinases, which were discovered in 1993 by John O’Shea, M.D. , NIAMS Scientific Director and Chief of the NIAMS Molecular Immunology and Inflammation Branch.
NIAMS Intramural Retreat
NIAMS Intramural researcher Martin Pelletier, Ph.D., discusses his research poster, "Characterization of the inflammatory processes involved in the familial autoinflammatory disease TRAPS," at the NIAMS Intramural Retreat, June 1, 2012.